Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Innovation and Development in Polymer Heart Valves: A New Era of Transcatheter Aortic Valve Replacement
Author(s): Yu Mao , Fengkai Liu , Xi Chen , et al Added: 6 months ago

Intervention
CRT 25: The PARTNER 3 Registry
Author(s): S. Chris Malaisrie Added: 1 year ago
CRT 25 - Dr S. Chris Malaisrie (Northwestern University, Evanston, US) joins us to discuss the five-year outcomes from the PARTNER 3 aortic valve-in-valve registry (NCT02675114). The prospective, randomized, multi-center study aimed to assess TAVR with the Edwards SAPIEN 3 transcatheter heart valve (Edwards Lifesciences) compared to aortic valve replacement with a commercially available surgical… View more

Intervention
TCT 25: The PREVUE-VALVE Study
Author(s): David J Cohen Added: 6 months ago
TCT 2025 - The PREVUE-VALVE study finds an 8.2% prevalence of moderate or greater valvular heart disease amongst Americans age 65-85, increasing to 18.4% when participants with mild to moderate VHD were included.Dr David J. Cohen (Cardiovascular Research Foundation & St Francis Hospital, US) joins us to discuss findings from the PREVUE-VALVE study, examining age and sex-specific prevalence of… View more

Imaging & Diagnostics

Intervention
Managing Pacemaker Leads in Tricuspid Valve Interventions
Author(s): Devi Nair , Laurence Epstein , Robert D Schaller Added: 7 months ago
In this essential episode of Rhythm Interventions Unplugged, host Dr Devi Nair (St. Bernard's Medical Center, US) sits down with two leading experts in cardiac device management: Dr Larry Epstein and Dr Robert Schaller. Together, they explore a critical challenge facing electrophysiologists today - managing pacemaker and ICD leads in patients requiring tricuspid valve interventions.Dr Epstein and… View more

Electrophysiology & Arrhythmia
New York Valves 2025
Author(s): Paul Grayburn Added: 10 months ago
Don't miss our late-breaking coverage of New York Valves 2025 Summit, including Expert Interviews offering insights into key data and their future impact on clinical practice. View more

Imaging & Diagnostics

Intervention
EuroPCR 25: The TRINITY Trial
Author(s): Thomas Modine Added: 12 months ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement… View more

Intervention
NY Valves 25: TRISCEND II Substudy
Author(s): Added: 10 months ago
New York Valves 25 - A substudy of TRISCEND II investigating the effect of transcatheter tricuspid valve replacement (TTVR) on preference-weighted health status showed significant benefits in patients who received TTVR.We are joined by Dr Suzanne Arnold (Saint Luke's Mid America Heart Institute, US) to discuss the findings from a substudy of the TRISCEND II trial, which aimed to create an… View more

Intervention
Atrioventricular (AV) Valves Summit 2024
Author(s): Marco Metra , Victoria Delgado , Nicole Karam , et al Added: 1 year ago
In this series of short interviews filmed at AV Valves Summit 2024, leading experts offer valuable insights and professional opinions on transcatheter mitral and tricuspid interventions.The sessions explore a wide array of topics, including advancements in TEER techniques, the evolving focus on patient quality of life, the ongoing debate between repair versus replacement, and the most effective… View more

Vascular Disease and Surgery
The Index Valve Matters: Optimal Index TAVI for Patients Lifetime Management
Author(s): Michael Joner Added: 4 months ago
In this interview, Prof Michael Joner (German Heart Centre, Munich, DE) discusses the specific needs and treatment considerations when managing low and intermediate risk TAVI patients. He also highlights the increasing need to consider future interventions when selecting the index valve.Prof Joner details the Navitor TAVI system resheathable design with intra-annular function, large-cell frame… View more

Intervention
LANDMARK: Myval THV Noninferior to Contemporary Valves
Added: 3 months ago Source:  Transcatheter Academy
One-year outcomes from the LANDMARK trial show the Myval transcatheter heart valve (THV) series is noninferior to contemporary THVs for treating symptomatic severe native aortic stenosis.¹ The results demonstrate comparable clinical efficacy and haemodynamic performance at 1 year.MethodologyLANDMARK (NCT04275726) was a prospective, randomised, open-label, noninferiority trial conducted across 31… View more

Demographic

Intervention